Researchers have found evidence that a natural extract of citrus can inhibit the growth of painful kidney stones and even dissolve the crystals.
The hydroxycitrate compound (HCA) dissolve the calcium oxalate, the most abundant element in the human kidney stones, according to the study forms the basis for the design of an effective drug for the painful condition.
“HCA shows promise as a potential therapy kidney stones to prevent” the researchers wrote in the study, published in the journal Nature Onlne.
The findings are the result of a combination of experimental studies, computer studies and human studies, said lead study author Jeffrey Rimer, an associate professor at the University of Houston in the United States ..
Kidney stones are small deposits, hard minerals that form in the kidneys. High blood pressure, diabetes and obesity can increase the risk and the incidence is increasing.
The preventive treatment has not changed much much in the last three decades. The doctors say that patients who are at risk, a lot of water and avoid developing drinking foods high in oxalate, such as rhubarb, okra, spinach and almonds calculating.
They recommend often citrate (CA) in the form of potassium citrate, a supplement that can slow the growth of crystals, but some people are unable to tolerate the side effects.
“HCA may be preferred as a therapy to CA (potassium citrate),” the researchers said.
HCA is chemically similar to the CA and is also available as a dietary supplement.
Studies in CA head to head and HCA determined that although both compounds inhibit the growth of calcium oxalate
HCA crystals was more powerful and unique features that are beneficial to the development of new therapies.
HCA has also been tested in human volunteers, seven people took the supplement for three days, so that the researchers that HCA to determine, is excreted in the urine, to work a prerequisite for the supplement as a treatment.
While Rimer said the investigation has established the basis for the development of an effective drug, questions remain. Long-term trials, the dose and safety are additional staff required, he said.